iRhythm Sets A $200 Million Buyback Ceiling — Its Board Can Pause Purchases
The cardiac-monitoring company expects to use available cash and operating cash to fund purchases.
iRhythm Holdings, which helps doctors diagnose irregular heart rhythms through wearable cardiac monitoring, authorized up to $200 million in stock buybacks Tuesday. The company announced the program Wednesday and detailed it in an SEC filing Thursday, with purchases discretionary and its board free to pause them.
Cash Funds The Repurchase Plan
iRhythm expects to pay for repurchases with cash it already has, including cash equivalents, and money generated by its operations. The authorization covers outstanding common shares.
Management will decide how much stock to buy and when, weighing market conditions against the company's needs. The board can revise the program, suspend it or end it altogether; iRhythm has no obligation to purchase a set dollar amount or share count.
The company can buy shares on the market, negotiate purchases privately or use accelerated repurchase arrangements. It may also arrange purchases through pre-scheduled trading plans filed with the SEC.
VitalConnect Adds To The Growth Bet
iRhythm tied the authorization to its assessment of its core business and the opportunities it sees in recently acquired VitalConnect, the business it has added to its operations. The acquisition is completed; realizing the benefits remains part of management's growth plan.
The company cautioned that those expected benefits depend on successfully integrating VitalConnect. It also cited competition, changes in reimbursement and regulation, and fluctuations in operating results among the risks facing its business.
From Heartbeat Data To Physician Reports
iRhythm's Zio system uses a wire-free wearable patch to record the heart's electrical signals for up to 14 days. Cloud-based software analyzes those recordings, and trained technicians at its Medicare-enrolled testing facilities review reports before prescribing physicians receive them.
The company sells monitoring services mainly in the United States to physician practices and health systems, including cardiologists and primary care doctors. It also operates commercially in the United Kingdom, selected European countries and Japan.
Since its first FDA clearance, iRhythm has delivered more than twelve million patient reports. That monitoring service remains the core business alongside the newly added VitalConnect operations.
The $200 million authorization gives iRhythm room to repurchase shares, while leaving the actual cash outlay to management and its board.
Sources
- 8-K Filing — iRhythm Holdings, Inc. (IRTC) — SEC EDGAR
- Exhibit tm2629543d1_ex99-1.htm — iRhythm Holdings, Inc. 8-K exhibit — SEC EDGAR
- iRhythm Announces Approval of $200 Million Share Repurchase — globenewswire.com